One-Lung Ventilation: Expression of Pulmonary Inflammatory Mediators - Full Text View

Sponsored by:	University of Zurich
Information provided by:	University of Zurich
ClinicalTrials.gov Identifier:	NCT00515905

Purpose

One-lung ventilation; organ protection; volatile anesthetics

One-lung ventilation has become a common procedure for thoracoscopic surgery. Two hypothesis will be tested in this study:

Are inflammatory mediators increased in the re-ventilated lung after short-period pulmonary collapse?
Does Sevoflurane influence the production of inflammatory mediators in the re-inflated lung? Therefore, this study will elucidate the potential protective effect of a volatile anaesthetic (sevoflurane) on the production of inflammatory mediators by the respiratory compartment of the lung, i.e. the alveolar epithelium.
- Trial with immunomodulatory product / biological

Condition	Intervention
Thoracic Surgery With One-Lung Ventilation	Drug: Sevoflurane/propofol

MedlinePlus related topics: Anesthesia

Drug Information available for: Propofol Sevoflurane

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment, Pharmacodynamics Study
Official Title:	Lung: One-Lung Ventilation: Expression of Pulmonary Inflammatory Mediators After Deflation and re-Expansion of the Lung During Thoracic Surgery

Further study details as provided by University of Zurich:

Primary Outcome Measures:

One-lung ventilation measurement in the re-ventilated lung after short-period pulmonary collapse [ Time Frame: Sep 07 ] [ Designated as safety issue: No ]

Estimated Enrollment:	76
Study Start Date:	October 2004
Estimated Study Completion Date:	September 2007
Estimated Primary Completion Date:	September 2007 (Final data collection date for primary outcome measure)

Intervention Details:

Sevoflurane/propofol

Eligibility

Ages Eligible for Study:	18 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion criteria:

Thoracic surgery (thoracotomy, thoracoscopy) with one-lung ventilation

Exclusion criteria:

Immunosuppressive therapy
Ongoing inflammatory processes

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00515905

Contacts

Contact: Beatrice Beck Schimmer, MD

+41 (0)44 255 11 11

beatrice.beck@usz.ch

Locations

Switzerland
University Hospital of Zurich	Recruiting
Zurich, Switzerland
Principal Investigator: beatrice beck schimmer, MD
University Hospital of Zurich	Recruiting
Zurich, Switzerland

Sponsors and Collaborators

University of Zurich

Investigators

Study Director:

01 Studienregister MasterAdmins

UniversitaetsSpital Zuerich

More Information

Responsible Party:	University of Zurich ( Beatrice Beck-Schimmer )
Study ID Numbers:	StV 20-2004
Study First Received:	August 13, 2007
Last Updated:	April 8, 2008
ClinicalTrials.gov Identifier:	NCT00515905
Health Authority:	Switzerland: Swissmedic

Study placed in the following topic categories:

Propofol
Sevoflurane

Additional relevant MeSH terms:

Anesthetics, Intravenous
Anesthetics, Inhalation
Anesthetics, General
Therapeutic Uses
Hematologic Agents
Hypnotics and Sedatives

Physiological Effects of Drugs
Central Nervous System Depressants
Anesthetics
Platelet Aggregation Inhibitors
Central Nervous System Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009